VIP–H: Very Important Pharmacogenes in Hmong

- Partners: SoLaHmo\(^1\), UMN\(^2\)· Hmong professionals\(^3\), with CAB\(^4\)
- Dates: 2016–2018
- Purpose:
  - Measure extent of pharmacogenes known to affect medication doses in the Hmong community
  - Evaluate people’s responses to their pharmacogenomic results
- Methods:
  - Genetic analysis in 198 Hmong adults to identify 24 genetic variations relevant to 20 medicines
  - Focus group discussions with 27 participants about their results
- Results
  - Significant genetic variations for two medicines (warfarin and clopidogrel), some variations for 8 medicines and little variations for 10 medicines.
  - Community members are interested in results. They perceive that heredity (ncaj cev) influences their composition (roj ntshav), which affects how medicines work for them.
- Poster
- Application: Communicating results at community events and VIP–Hmong website
- Funder: UMN Grand Challenges Grant
- Team Members: Koobmeej Lee\(^1\), Txia Xiong\(^1\), Kathie Culhane–Pera\(^1\), Robert J. Straka\(^3\), Jeffrey Bishop\(^3\), Kerui Peng\(^3\), Bharat Thyagarajan\(^3\), Ya–Feng Wen\(^3\), Heather Zierhut\(^3\), Donna Lee\(^4\), May Xia Lo\(^4\), Der Moua\(^4\), Steve Mouacheupao\(^4\), Ka Her Vang\(^4\), Kauchee Vang\(^4\)